New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 11, 2013
08:29 EDTSRPTSarepta's eteplirsen accelerated approval could be denied, TheStreet.com reports
According to TheStreet.com, accelerated approval for Sarepta's (SRPT) eteplirsen, a novel experimental drug for Duchenne Muscular Dystrophy, will be denied by the FDA. Instead, TheStreet says it is more likely Sarepta will be required to perform a larger pivotal study prior to submitting the drug for FDA review. Reference Link
News For SRPT From The Last 14 Days
Check below for free stories on SRPT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 19, 2014
20:24 EDTSRPTSarepta shares could double, Barron's says
Subscribe for More Information
April 8, 2014
14:44 EDTSRPTInvestors await eteplirsen news from Sarepta amid speculation, TheStreet says
Subscribe for More Information
09:13 EDTSRPTSarepta April volatility increases to 166
Subscribe for More Information
April 7, 2014
11:11 EDTSRPTSarepta said to cancel appearance at Needham conference
Sarepta cancelled its appearance at Needham's conference tomorrow due to "other obligations," a re-tweet by The Street's Adam Feuerstein says, citing a confirmation from the company. Shares of Sarepta moved up 23c to $23.37 following circulation of the tweet.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use